Hanimune Therapeutics has developed proprietary technology that will transform food allergy treatment. There are currently no effective and safe treatments for the 35 mm Americans that live with the daily risk of anaphylaxis.
Our patented process safely induces the immune system to tolerate allergens without causing allergic reactions during treatment, promising a true cure.
Hanimune Therapeutics' lead candidate aims to be the first safe, effective, and well-tolerated treatment for hen's egg allergy, a leading cause of anaphylaxis and accidental death. Our pipeline includes treatments for several other food allergies, including milk, peanut and shellfish.
Hanimune Therapeutics was founded in 2018 to bring food science together with immunology to unearth novel mechanisms for food allergy treatment. The company is headquartered in Pennsylvania.